Morepen Laboratories Limited

BSE:500288 Stock Report

Market Cap: ₹43.8b

Morepen Laboratories Past Earnings Performance

Past criteria checks 4/6

Morepen Laboratories has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 13.6% per year. Morepen Laboratories's return on equity is 11.9%, and it has net margins of 7.4%.

Key information

11.3%

Earnings growth rate

7.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate13.6%
Return on equity11.9%
Net Margin7.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Morepen Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:500288 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2417,7481,3132,0170
30 Jun 2417,5711,1771,9980
31 Mar 2417,0199621,9350
31 Dec 2316,4227612,1270
30 Sep 2315,4335311,9580
30 Jun 2315,2384772,8840
31 Mar 2314,2203871,6540
31 Dec 2214,2704281,8000
30 Sep 2214,7655531,8430
30 Jun 2214,7217682,6040
31 Mar 2215,5581,0171,7240
31 Dec 2114,7431,1611,8090
30 Sep 2113,8541,1841,5890
30 Jun 2113,2951,0822,0920
31 Mar 2111,9809711,4070
31 Dec 2011,1368141,3450
30 Sep 2010,3806841,2790
30 Jun 209,1834531,6780
31 Mar 208,5843361,1430
31 Dec 198,7313311,1610
30 Sep 198,5303121,1180
30 Jun 198,1173401,4740
31 Mar 197,7142889950
31 Dec 187,2582529800
30 Sep 186,6722678790
30 Jun 186,4363088410
31 Mar 186,1012968070
31 Mar 175,9912367390
31 Mar 164,8611286160
31 Mar 154,014215170
31 Mar 143,670-288074

Quality Earnings: 500288 has a high level of non-cash earnings.

Growing Profit Margin: 500288's current net profit margins (7.4%) are higher than last year (3.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 500288's earnings have grown by 11.3% per year over the past 5 years.

Accelerating Growth: 500288's earnings growth over the past year (147.1%) exceeds its 5-year average (11.3% per year).

Earnings vs Industry: 500288 earnings growth over the past year (147.1%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 500288's Return on Equity (11.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 09:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Morepen Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vijay MadunalaFirstCall Research